Basel Medical FY2026: Revenue Up 45% to S$16.4M, But Material Weakness and Going-Concern Dependency Disclosed
BMGL sits 95% above its 52-week low of $2.56.
Summary
Basel Medical's FY2026 20-F shows revenue up 45.2% to S$16.4 million and a much smaller loss, but cash is down to S$0.53 million, going concern depends on shareholder support and new financing, and management disclosed a material weakness in internal controls.
Key Events · Earnings and Guidance · BMGL
-
FY2026 Revenue Jumps 45.2%
Revenue rose to S$16,441,770 (US$12,808,828) from S$11,319,944, driven by higher business activity and demand for the group's clinic services.
-
Loss Narrows on Goodwill Base Effect
Loss before tax fell to S$1,249,833 (US$973,673) from S$11,053,571, a year that carried a S$10,349,252 full goodwill impairment on the Bethesda acquisition; FY2026 had no such charge.
-
Cash Drops to S$0.53 Million
Cash and cash equivalents fell to S$529,887 (US$409,464) from S$3,044,466, with S$635,207 used in operating activities and S$2,868,009 paid on lease principal.
-
Going Concern Rests on Outside Support
The filing states continuation as a going concern depends on the major shareholder's financial support, sustainable operating cash flows over the next 12 months, and the ability to procure additional financing.
Analysis · BMGL · Industrial Applications And Services
Revenue grew 45.2% to S$16.44 million and the loss before tax narrowed to S$1.25 million from S$11.05 million — but last year's number was dominated by a S$10.35 million goodwill write-off on the Bethesda acquisition, so the improvement is mostly the absence of that charge rather than an operating turnaround. The bigger issue is the balance sheet: cash fell to S$0.53 million from S$3.04 million, operating activities burned S$0.64 million, and the company states its going-concern basis depends on its major shareholder's support, sustainable cash generation, and its ability to raise more financing. Management also disclosed a material weakness in internal control over financial reporting tied to insufficient IFRS-skilled staff and concluded disclosure controls were not effective at June 30, 2026. The October 2026 raise (US$7.98 million gross, ~US$7.42 million net) is what keeps the lights on near term, and the filing flags that the 6 million common warrants — exercisable on a zero-cash basis — would substantially dilute holders if used.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BMGL was trading at $4.99 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $37.8M. The 52-week trading range was $2.56 to $19.92. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.